Differential Diagnosis of Suspected COPD Exacerbations in the Acute Care Setting: Best Practice
enero 26, 2023
Approximately 25% and 65% of patients hospitalized for an ECOPD die within 1 and 5 years, respectively.
Approximately 25% and 65% of patients hospitalized for an ECOPD die within 1 and 5 years, respectively.
The European Respiratory Journal is voluntarily reviewed. We are most grateful for the hard work and dedication of all those who reviewed articles for the ERJ in 2022.
Evidence from clinical studies indicates that the inhaled corticosteroids (ICS) routinely taken for asthma and COPD could have had a protective role in preventing severe COVID-19 and, therefore, may be a promising treatment for COVID-19.
«Chronic airway diseases such as asthma and chronic obstructive pulmonary disease are prevalent and complex conditions that often coexist in the same patient. To address this complexity in clinical practice, and to move forward toward personalized and precision…»
Clinical trials evaluating the management of acute exacerbations of COPD assess heterogeneous outcomes, often omitting those that are clinically relevant or more important to patients. (…)
«Chronic airway diseases such as asthma and chronic obstructive pulmonary disease are prevalent and complex conditions that often coexist in the same patient. To address this complexity in clinical practice, and to move forward toward personalized and precision…»
Chronic obstructive pulmonary disease (COPD) is the end result of a series of dynamic and cumulative gene-environment interactions over a lifetime…
The addition of inhaled budesonide to usual care is safe and may reduce the risk of disease progression in patients hospitalised because of COVID-19 pneumonia
Entrevista a Alvar Agutí en periódico digital El Español, donde habla extensamente no sólo de su experiencia como profesional y experto en la EPOC, sino como paciente afectado del síndrome Guillaín-Barré, ingresado en su propio hospital, desde el que tuvo que volver a aprender a hablar, escribir, andar… con 60 años: